Novel medical imaging system to assist
surgeons with real-time margin visualization in the OR
Pavilion Surgery Center, an affiliate of St. Joseph Hospital,
along with Perimeter Medical Imaging AI, Inc.
(TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”) –
a medical technology company driven to transform cancer surgery
with ultra-high-resolution, real-time, advanced imaging tools to
address high unmet medical needs – today jointly announced the
first commercial placement of the Perimeter S-Series OCT system in
the state of California at Pavilion Surgery Center in Orange, CA.
The new medical imaging technology will be used under the direction
of Michele Carpenter, MD, a breast surgeon who performs breast
conservation and other surgeries at Pavilion Surgery Center.
Perimeter S-Series OCT received FDA 510(k) clearance in 2021 and
is a medical imaging tool that uses Optical Coherence Tomography
(OCT) to provide clinicians with cross-sectional, real-time margin
visualization (1-2 mm below the surface) of an excised tissue
specimen.
Michele Carpenter, MD, FACS, Breast Program Director, The Center
for Cancer Prevention and Treatment, St. Joseph Hospital, Orange,
CA, commented, “For years, breast surgeons have worried about not
getting clean margins the first time they do a lumpectomy for
breast cancer. With the Perimeter S-Series OCT system, we have a
much better chance of doing that the first time.”
Alejandro Ramirez, MD, Medical Director, Chief of Medical Staff,
Pavilion Surgery Center, said, “As part of Pavilion’s commitment to
clinical excellence and innovation, we highly value the Perimeter
S-Series OCT system to ensure the best outcome for our
patients.”
Steve Sapot, Perimeter’s Chief Commercial Officer, stated, “This
placement of the Perimeter S-Series OCT system is another
successful outcome of our many market development activities
underway across the U.S. Our sales team continues to connect with
leading healthcare institutions to train and support innovative
physicians who see the true benefits of using Perimeter’s
technology in their surgical practices. We remain laser-focused on
bringing Perimeter’s transformative ultra-high resolution medical
imaging technology directly into the OR to assist the surgeon with
real-time intraoperative margin visualization – with the aim of
improving patient outcomes and reducing healthcare costs.”
About Perimeter S-Series OCT
Cleared by the FDA as an imaging tool in the evaluation of
excised tissue microstructure, the company is bringing the
Perimeter S-Series Optical Coherence Tomography (OCT) system to
leading surgeons in hospitals across the U.S. Perimeter S-Series
OCT gives physicians the ability to visualize microscopic tissue
structures at the point-of-care – during the primary surgery
compared to days later when pathology reports are available. This
novel technology provides cross-sectional images of tissues down to
2mm depth, with 10x higher image resolution than standard x-ray and
ultrasound. Giving physicians the ability to visualize microscopic
tissue structures real-time in the operating room has the potential
to result in better long-term outcomes for patients and lower costs
to the healthcare system.
About Pavilion Surgery Center
Pavilion Surgery Center is one of Orange County’s premier
healthcare facilities and one of the most technologically advanced
outpatient surgical facilities in the greater Orange area.
Affiliated with Providence St. Joseph Hospital, the center is
physician-run and home to the latest advances in technology and
equipment, many of the area’s most reputable physicians and
surgeons, and a hand-picked team of experienced and highly trained
nurses and technicians. Pavilion Surgery Center is a
multi-specialty surgical center, with 12 ORs and 4 GI suites.
About Perimeter Medical Imaging AI, Inc.
Based in Toronto, Canada and Dallas, Texas, Perimeter Medical
Imaging AI (TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical
technology company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
areas of high unmet medical need. Available across the U.S., our
FDA-cleared Perimeter S-Series OCT system provides real-time,
cross-sectional visualization of excised tissues at the cellular
level. The breakthrough-device-designated investigational Perimeter
B-Series OCT with ImgAssist AI represents our next-generation,
artificial intelligence technology that is currently under clinical
development. The company’s ticker symbol “PINK” is a reference to
the pink ribbons used during Breast Cancer Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements
This news release contains statements that constitute
“forward-looking information” within the meaning of applicable
Canadian securities legislation. In this news release, words such
as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,”
“anticipate,” “intend,” “plan,” “estimate,” and similar words and
the negative form thereof are used to identify forward-looking
statements. Forward-looking information may relate to management’s
future outlook and anticipated events or results and may include
statements or information regarding the future financial position,
business strategy and strategic goals, competitive conditions,
research and development activities, projected costs and capital
expenditures, research and clinical testing outcomes, taxes and
plans and objectives of, or involving, Perimeter. Without
limitation, information regarding the potential benefits of
Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter
ImgAssist are forward-looking information. Forward-looking
statements should not be read as guarantees of future performance
or results, and will not necessarily be accurate indications of
whether, or the times at or by which, any particular result will be
achieved. No assurance can be given that any events anticipated by
the forward-looking information will transpire or occur.
Forward-looking information is based on information available at
the time and/or management’s good-faith belief with respect to
future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter’s control. Such forward-looking
statements reflect Perimeter’s current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter’s
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter’s
Management Discussion and Analysis for the year ended December 31,
2021, which is available on Perimeter’s SEDAR profile at
www.sedar.com, and could cause actual events or results to differ
materially from those projected in any forward-looking statements.
Perimeter does not intend, nor does Perimeter undertake any
obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220803005270/en/
Jodi Regts Perimeter Medical Imaging AI, Inc. Direct:
469-743-1834 Toll-free: 888-988-7465 (PINK) Investors:
investors@perimetermed.com Media: media@perimetermed.com
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025